Clinical trial
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
NCT07224321
Study timeline
Study start (actual)2026-02-04Date precision: day
Registry last updated2026-08-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 1 Diabetes Mellitusunresolved
Interventions
Sponsors & collaborators
Mannkind Corporationlead sponsor
Jaeb Center for Health Researchcollaborator
Mapped research locations
HoustonTexas, United States1BostonMassachusetts, United States1Los AngelesCalifornia, United States1San FranciscoCalifornia, United States1IndianapolisIndiana, United States1AuroraColorado, United States1Oklahoma CityOklahoma, United States1New HavenConnecticut, United States1CharlottesvilleVirginia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07224321 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.